Investig Clin Urol.  2016 Jun;57(Suppl 1):S26-S35. 10.4111/icu.2016.57.S1.S26.

Treatment of bladder cancer in the elderly

• Erlich A
• Zlotta AR

• KMID: 2426514
• DOI: http://doi.org/10.4111/icu.2016.57.S1.S26

Abstract

As the population ages and life expectancy increases in the human population, more individuals will be diagnosed with bladder cancer (BC). The definition of who is elderly is likely to change in the future from the commonly used cut-off of ≥75 years of age. Physiological rather than chronological age is key. BC care in the elderly is likely to become a very common problem in daily practice. Concerns have been raised that senior BC patients are not given treatments that could cure their disease. Clinicians lack quantitative and reliable estimates of competing mortality risks when considering treatments for BC. Majority of patients diagnosed with BC are elderly, making treatment decisions complex with their increasing number of comorbidities. A multidisciplinary approach to these patients may be a way to incorporate discussion from various disciplines regarding treatment options available. Here we review various treatment options for elderly patients with muscle invasive BC and nonmuscle invasive BC. We include differences in treatments from robotic versus open radical cystectomy, various urinary diversion techniques, chemotherapy, radiation therapy and combination treatments. In clinical practice, treatment decisions for elderly patients should be done on a case-by-case basis, tailored to each patient with their specific histories and comorbidities considered. Some healthy elderly patients may be better candidates for extensive curative treatments than their younger counterparts. This implies that these important, life-altering decisions cannot be solely based on age as many other factors can affect patient survival outcomes.

Keyword

Bladder cancer; Cystectomy; Elderly; Geriatric; Treatment

MeSH Terms

Age Factors
Aged
Clinical Decision-Making/methods
Combined Modality Therapy
Comorbidity
Cystectomy/methods
Humans
Life Expectancy
Prognosis
Robotic Surgical Procedures/methods
Urinary Bladder Neoplasms/*therapy

Figure

• 

  Fig. 1 Incidence of adverse events within 90 days by organ system. Adapted from Nazmy et al. J Urol 2014;191:681-7, with permission of Elsevier [81].

Reference

1. Surveillance, Epidemiology, and End Research Program. SEER stat fact sheets: bladder cancer [Internet]. Bethesda (MD): National Cancer Institute;2016. cited 2016 May 1. Available from: http://seer.cancer.gov/statfacts/html/urinb.html.

2. Shariat SF, Milowsky M, Droller MJ. Bladder cancer in the elderly. Urol Oncol. 2009; 27:653–667. PMID: 19879476.

3. Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2015. Toronto (ON): Canadian Cancer Society;2015.

4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66:7–30. PMID: 26742998.

5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65:5–29. PMID: 25559415.

6. Statistics Canada. Annual demographic estimates: Canada, provinces and territories 2012 [Internet]. Otawa (ON): Statistics Canada;2012. cited 2016 May 1. Available from: www.statcan.gc.ca/pub/91-215-x/91-215-x2012000-eng.pdf.

7. Statistics Canada. Population projections for Canada, provinces and territories (91-520-X) [Internet]. Otawa (ON): Statistics Canada;2016. cited 2016 May 1. Available from: http://www5.statcan.gc.ca/olc-cel/olc.action?objId=91-520-X&objType=2&lang=en&limit=0.

8. Noon AP, Albertsen PC, Thomas F, Rosario DJ, Catto JW. Competing mortality in patients diagnosed with bladder cancer: evidence of undertreatment in the elderly and female patients. Br J Cancer. 2013; 108:1534–1540. PMID: 23481180.

9. Gore JL, Litwin MS, Lai J, Yano EM, Madison R, Setodji C, et al. Use of radical cystectomy for patients with invasive bladder cancer. J Natl Cancer Inst. 2010; 102:802–811. PMID: 20400716.

10. Leveridge MJ, Siemens DR, Mackillop WJ, Peng Y, Tannock IF, Berman DM, et al. Radical cystectomy and adjuvant chemotherapy for bladder cancer in the elderly: a population-based study. Urology. 2015; 85:791–798. PMID: 25661830.

11. Froehner M, Brausi MA, Herr HW, Muto G, Studer UE. Complications following radical cystectomy for bladder cancer in the elderly. Eur Urol. 2009; 56:443–454. PMID: 19481861.

12. Megwalu II, Vlahiotis A, Radwan M, Piccirillo JF, Kibel AS. Prognostic impact of comorbidity in patients with bladder cancer. Eur Urol. 2008; 53:581–589. PMID: 17997024.

13. Ha MS, Chang IH. Significance of age and comorbidity as prognostic indicators for patients with bladder cancer. Asian J Androl. 2010; 12:766–774. PMID: 20676116.

14. Fairey AS, Jacobsen NE, Chetner MP, Mador DR, Metcalfe JB, Moore RB, et al. Associations between comorbidity, and overall survival and bladder cancer specific survival after radical cystectomy: results from the Alberta Urology Institute Radical Cystectomy database. J Urol. 2009; 182:85–92. PMID: 19447413.

15. Grubmueller B, Seitz C, Shariat SF. The treatment of muscleinvasive bladder cancer in geriatric patients. Curr Opin Urol. 2016; 26:160–164. PMID: 26765044.

16. Hermanns T, Wei Y, Bhindi B, Satkunasivam R, Athanasopoulos P, Bostrom PJ, et al. A multidisciplinary bladder cancer clinic delivers personalized care for complex bladder cancer patients. Eur Urol Suppl. 2014; 13:e793.

17. Rink M, Dahlem R, Kluth L, Minner S, Ahyai SA, Eichelberg C, et al. Older patients suffer from adverse histopathological features after radical cystectomy. Int J Urol. 2011; 18:576–584. PMID: 21699582.

18. May M, Fritsche HM, Gilfrich C, Brookman-May S, Burger M, Otto W, et al. Influence of older age on survival after radical cystectomy due to urothelial carcinoma of the bladder: survival analysis of a German multi-centre study after curative treatment of urothelial carcinoma of the bladder. Urologe A. 2011; 50:821–829. PMID: 21340593.

19. Nielsen ME, Shariat SF, Karakiewicz PI, Lotan Y, Rogers CG, Amiel GE, et al. Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol. 2007; 51:699–706. PMID: 17113703.

20. Fleshner NE, Herr HW, Stewart AK, Murphy GP, Mettlin C, Menck HR. The National Cancer Data Base report on bladder carcinoma. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1996; 78:1505–1513. PMID: 8839558.

21. Bhindi B, Yu J, Kuk C, Sridhar SS, Hamilton RJ, Finelli A, et al. The importance of surgeon characteristics on impacting oncologic outcomes for patients undergoing radical cystectomy. J Urol. 2014; 192:714–719. PMID: 24594406.

22. Schrag D, Mitra N, Xu F, Rabbani F, Bach PB, Herr H, et al. Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. Urology. 2005; 65:1118–1125. PMID: 15922428.

23. Fedeli U, Fedewa SA, Ward EM. Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J Urol. 2011; 185:72–78. PMID: 21074192.

24. Chamie K, Hu B, Devere White RW, Ellison LM. Cystectomy in the elderly: does the survival benefit in younger patients translate to the octogenarians? BJU Int. 2008; 102:284–290. PMID: 18410437.

25. Prout GR Jr, Wesley MN, Yancik R, Ries LA, Havlik RJ, Edwards BK. Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study. Cancer. 2005; 104:1638–1647. PMID: 16130136.

26. Hollenbeck BK, Miller DC, Taub D, Dunn RL, Khuri SF, Henderson WG, et al. Identifying risk factors for potentially avoidable complications following radical cystectomy. J Urol. 2005; 174(4 Pt 1):1231–1237. PMID: 16145376.

27. Konety BR, Dhawan V, Allareddy V, Joslyn SA. Impact of hospital and surgeon volume on in-hospital mortality from radical cystectomy: data from the health care utilization project. J Urol. 2005; 173:1695–1700. PMID: 15821560.

28. Shabsigh A, Korets R, Vora KC, Brooks CM, Cronin AM, Savage C, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol. 2009; 55:164–174. PMID: 18675501.

29. Guancial EA, Roussel B, Bergsma DP, Bylund KC, Sahasrabudhe D, Messing E, et al. Bladder cancer in the elderly patient: challenges and solutions. Clin Interv Aging. 2015; 10:939–949. PMID: 26089655.

30. Daneshmand S, Ahmadi H, Schuckman AK, Mitra AP, Cai J, Miranda G, et al. Enhanced recovery protocol after radical cystectomy for bladder cancer. J Urol. 2014; 192:50–55. PMID: 24518775.

31. Horovitz D, Turker P, Bostrom PJ, Mirtti T, Nurmi M, Kuk C, et al. Does patient age affect survival after radical cystectomy? BJU Int. 2012; 110(11 Pt B):E486–E493. PMID: 22551360.

32. Siddiqui KM, Izawa JI. Ileal conduit: standard urinary diversion for elderly patients undergoing radical cystectomy. World J Urol. 2016; 34:19–24. PMID: 26475274.

33. Mühlberg W, Platt D. Age-dependent changes of the kidneys: pharmacological implications. Gerontology. 1999; 45:243–253. PMID: 10460985.

34. Clark PE, Stein JP, Groshen SG, Cai J, Miranda G, Lieskovsky G, et al. Radical cystectomy in the elderly: comparison of clincal outcomes between younger and older patients. Cancer. 2005; 104:36–43. PMID: 15912515.

35. Donat SM, Siegrist T, Cronin A, Savage C, Milowsky MI, Herr HW. Radical cystectomy in octogenarians: does morbidity outweigh the potential survival benefits? J Urol. 2010; 183:2171–2177. PMID: 20399461.

36. Sogni F, Brausi M, Frea B, Martinengo C, Faggiano F, Tizzani A, et al. Morbidity and quality of life in elderly patients receiving ileal conduit or orthotopic neobladder after radical cystectomy for invasive bladder cancer. Urology. 2008; 71:919–923. PMID: 18355900.

37. Skinner EC, Stein JP, Skinner DG. Surgical benchmarks for the treatment of invasive bladder cancer. Urol Oncol. 2007; 25:66–71. PMID: 17208142.

38. Aziz A, May M, Burger M, Palisaar RJ, Trinh QD, Fritsche HM, et al. Prediction of 90-day mortality after radical cystectomy for bladder cancer in a prospective European multicenter cohort. Eur Urol. 2014; 66:156–163. PMID: 24388438.

39. Bostrom PJ, Kossi J, Laato M, Nurmi M. Risk factors for mortality and morbidity related to radical cystectomy. BJU Int. 2009; 103:191–196. PMID: 18671789.

40. Zebic N, Weinknecht S, Kroepfl D. Radical cystectomy in patients aged > or = 75 years: an updated review of patients treated with curative and palliative intent. BJU Int. 2005; 95:1211–1214. PMID: 15892803.

41. Mendiola FP, Zorn KC, Gofrit ON, Mikhail AA, Orvieto MA, Msezane LP, et al. Cystectomy in the ninth decade: operative results and long-term survival outcomes. Can J Urol. 2007; 14:3628–3634. PMID: 17784983.

42. Nielsen ME, Mallin K, Weaver MA, Palis B, Stewart A, Winchester DP, et al. Association of hospital volume with conditional 90-day mortality after cystectomy: an analysis of the National Cancer Data Base. BJU Int. 2014; 114:46–55. PMID: 24219110.

43. Schiffmann J, Gandaglia G, Larcher A, Sun M, Tian Z, Shariat SF, et al. Contemporary 90-day mortality rates after radical cystectomy in the elderly. Eur J Surg Oncol. 2014; 40:1738–1745. PMID: 25454826.

44. Hugen CM, Daneshmand S. Orthotopic urinary diversion in the elderly. World J Urol. 2016; 34:13–18. PMID: 26410825.

45. Deliveliotis C, Papatsoris A, Chrisofos M, Dellis A, Liakouras C, Skolarikos A. Urinary diversion in high-risk elderly patients: modified cutaneous ureterostomy or ileal conduit? Urology. 2005; 66:299–304. PMID: 16040096.

46. Ali AS, Hayes MC, Birch B, Dudderidge T, Somani BK. Health related quality of life (HRQoL) after cystectomy: comparison between orthotopic neobladder and ileal conduit diversion. Eur J Surg Oncol. 2015; 41:295–299. PMID: 24913090.

47. Anderson CB, Feurer ID, Large MC, Steinberg GD, Barocas DA, Cookson MS, et al. Psychometric characteristics of a condition-specific, health-related quality-of-life survey: the FACT-Vanderbilt Cystectomy Index. Urology. 2012; 80:77–83. PMID: 22608798.

48. Wuethrich PY, Vidal A, Burkhard FC. There is a place for radical cystectomy and urinary diversion, including orthotopic bladder substitution, in patients aged 75 and older: Results of a retrospective observational analysis from a high-volume center. Urol Oncol. 2016; 34:58.e19–58.e27. PMID: 26420022.

49. Longo N, Imbimbo C, Fusco F, Ficarra V, Mangiapia F, DiLorenzo G, et al. Complications and quality of life in elderly patients with high comorbidities who underwent cutaneous ureterostomy with single stoma or ileal conduit after radical cystectomy. BJU Int. 2016; 3. 02. [Epub]. DOI: 10.1111/bju.13462.

50. Bilimoria KY, Liu Y, Paruch JL, Zhou L, Kmiecik TE, Ko CY, et al. Development and evaluation of the universal ACS NSQIP surgical risk calculator: a decision aid and informed consent tool for patients and surgeons. J Am Coll Surg. 2013; 217:833–842. PMID: 24055383.

51. Hurria A, Cirrincione CT, Muss HB, Kornblith AB, Barry W, Artz AS, et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol. 2011; 29:1290–1296. PMID: 21357782.

52. Isbarn H, Jeldres C, Zini L, Perrotte P, Baillargeon-Gagne S, Capitanio U, et al. A population based assessment of perioperative mortality after cystectomy for bladder cancer. J Urol. 2009; 182:70–77. PMID: 19447427.

53. Feng MA, McMillan DT, Crowell K, Muss H, Nielsen ME, Smith AB. Geriatric assessment in surgical oncology: a systematic review. J Surg Res. 2015; 193:265–272. PMID: 25091339.

54. Galsky MD. How I treat bladder cancer in elderly patients. J Geriatr Oncol. 2015; 6:1–7. PMID: 25482022.

55. Terret C, Perol D, Albrand G, Droz JP. Quality of life in geriatric oncology: an evaluation of standard questionnaires in elderly men with urological malignancies. Crit Rev Oncol Hematol. 2011; 77:201–209. PMID: 20338777.

56. Surbone A, Kagawa-Singer M, Terret C, Baider L. The illness trajectory of elderly cancer patients across cultures: SIOG position paper. Ann Oncol. 2007; 18:633–638. PMID: 17028242.

57. Terret C, Droz JP. Editorial. The perception and dissemination of geriatric oncology. Crit Rev Oncol Hematol. 2010; 75:43–46. PMID: 20537904.

58. Xia L, Wang X, Xu T, Zhang X, Zhu Z, Qin L, et al. Robotic versus open radical cystectomy: an updated systematic review and meta-analysis. PLoS One. 2015; 10:e0121032. PMID: 25825873.

59. Ishii H, Rai BP, Stolzenburg JU, Bose P, Chlosta PL, Somani BK, et al. Robotic or open radical cystectomy, which is safer? A systematic review and meta-analysis of comparative studies. J Endourol. 2014; 28:1215–1223. PMID: 25000311.

60. Lin T, Fan X, Zhang C, Xu K, Liu H, Zhang J, et al. A prospective randomised controlled trial of laparoscopic vs open radical cystectomy for bladder cancer: perioperative and oncologic outcomes with 5-year follow-upT Lin et al. Br J Cancer. 2014; 110:842–849. PMID: 24407192.

61. Musch M, Janowski M, Steves A, Roggenbuck U, Boergers A, Davoudi Y, et al. Comparison of early postoperative morbidity after robot-assisted and open radical cystectomy: results of a prospective observational study. BJU Int. 2014; 113:458–467. PMID: 24053793.

62. Phillips EA, Uberoi V, Tuerk IA. Robot-assisted radical cystectomy in octogenarians. J Endourol. 2014; 28:219–223. PMID: 24074288.

63. Teishima J, Hieda K, Inoue S, Goto K, Ikeda K, Ohara S, et al. Comparison of initial experiences of robot-assisted radical cystectomy with those of laparoscopic for bladder cancer. Innovations (Phila). 2014; 9:322–326. PMID: 25062101.

64. Zeng S, Zhang Z, Yu X, Song R, Wei R, Zhao J, et al. Laparoscopic versus open radical cystectomy for elderly patients over 75-year-old: a single center comparative analysis. PLoS One. 2014; 9:e98950. PMID: 24901359.

65. Nix J, Smith A, Kurpad R, Nielsen ME, Wallen EM, Pruthi RS. Prospective randomized controlled trial of robotic versus open radical cystectomy for bladder cancer: perioperative and pathologic results. Eur Urol. 2010; 57:196–201. PMID: 19853987.

66. Nguyen DP, Al Hussein Al Awamlh B, Charles Osterberg E, Chrystal J, Flynn T, Lee DJ, et al. Postoperative complications and short-term oncological outcomes of patients aged ≥80 years undergoing robot-assisted radical cystectomy. World J Urol. 2015; 33:1315–1321. PMID: 25410374.

67. Bochner BH, Sjoberg DD, Laudone VP;. A randomized trial of robot-assisted laparoscopic radical cystectomy. N Engl J Med. 2014; 371:389–390. PMID: 25054732.

68. Bochner BH, Dalbagni G, Sjoberg DD, Silberstein J, Keren Paz GE, Donat SM, et al. Comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: a randomized clinical trial. Eur Urol. 2015; 67:1042–1050. PMID: 25496767.

69. Smith ND, Castle EP, Gonzalgo ML, Svatek RS, Weizer AZ, Montgomery JS, et al. The RAZOR (randomized open vs robotic cystectomy) trial: study design and trial update. BJU Int. 2015; 115:198–205. PMID: 25626182.

70. Nayan M, Bhindi B, Yu JL, Mamdani M, Fleshner NE, Hermanns T, et al. The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: a time-series analysis. Can Urol Assoc J. 2016; 10:25–30. PMID: 26977202.

71. Mathieu R, Lucca I, Klatte T, Babjuk M, Shariat SF. Trimodal therapy for invasive bladder cancer: is it really equal to radical cystectomy? Curr Opin Urol. 2015; 25:476–482. PMID: 26125510.

72. Rose TL, Milowsky MI. Management of muscle-invasive bladder cancer in the elderly. Curr Opin Urol. 2015; 25:459–467. PMID: 26075567.

73. Bassett JC, Chang SS. Treating octogenarians with muscle-invasive bladder cancer: preoperative opportunities for increasing the benefits of surgical intervention. Urol Oncol. 2014; 32:37.e13–37.e16. PMID: 23628313.

74. Hong NJ, Wright FC, Gagliardi AR, Paszat LF. Examining the potential relationship between multidisciplinary cancer care and patient survival: an international literature review. J Surg Oncol. 2010; 102:125–134. PMID: 20648582.

75. Galsky MD, Krege S, Lin CC, Hahn N, Ecke TH, Moshier E, et al. Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer. Urol Oncol. 2014; 32:30.e15–30.e21. PMID: 23428534.

76. Clayman RH, Shipley WU, Galland-Girodet S, Niemierko A, Gray PJ, Paly J, et al. Outcomes of selective bladder preservation in the elderly treated with conservative surgery and chemoradiation. Int J Radiat Oncol Biol Phys. 2013; 87(2 Suppl):S83.

77. Kouloulias V, Tolia M, Kolliarakis N, Siatelis A, Kelekis N. Evaluation of acute toxicity and symptoms palliation in a hypofractionated weekly schedule of external radiotherapy for elderly patients with muscular invasive bladder cancer. Int Braz J Urol. 2013; 39:77–82. PMID: 23489500.

78. Joudi FN, Smith BJ, O'Donnell MA, Konety BR. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol. 2006; 175:1634–1639. PMID: 16600718.

79. Herr HW. Age and outcome of superficial bladder cancer treated with bacille Calmette-Guerin therapy. Urology. 2007; 70:65–68. PMID: 17656210.

80. Margel D, Alkhateeb SS, Finelli A, Fleshner N. Diminished efficacy of Bacille Calmette-Guérin among elderly patients with nonmuscle invasive bladder cancer. Urology. 2011; 78:848–854. PMID: 21840578.

81. Nazmy M, Yuh B, Kawachi M, Lau CS, Linehan J, Ruel NH, et al. Early and late complications of robot-assisted radical cystectomy: a standardized analysis by urinary diversion type. J Urol. 2014; 191:681–687. PMID: 24099746.